stock market courses


Click to enlarge

Photo Credit: WSJ

US Bancorp (NYSE:USB) has long enjoyed a premium valuation over the rest of the large banks our country has to offer. The bank’s ability to generate other worldly returns when the rest of the industry seems to struggle has no doubt contributed to investors’ love affair with the stock. That has resulted in a stock that seems very expensive relative to its peers at all times but is USB good enough to have earned that distinction? Operating on the assumption that bank valuations are driven largely by return on equity, I’ll take a look at USB’s balance sheet and ROE for the past decade and determine if it is still worthy of its lofty valuation.

stock market courses: Veritiv Corporation(VRTV)


Advisors’ Opinion:

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha) Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha) CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update. Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million. The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62. Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold. Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split. Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period. AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016. Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli

stock market courses: Ring Energy, Inc.(REI)


Advisors’ Opinion:

  • [By Monica Gerson]

    Ring Energy Inc (NYSE: REI) is projected to post a quarterly loss at $0.05 per share on revenue of $7.92 million.

    Gain Capital Holdings Inc (NYSE: GCAP) is estimated to post its quarterly earnings at $0.07 per share on revenue of $100.39 million.

stock market courses: Portola Pharmaceuticals, Inc.(PTLA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 23 percent to $21.92 after announcing Phase III Betrixaban results.


    Shares of Spark Energy Inc (NASDAQ: SPKE) were down 16 percent to $20.43. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.

  • [By Todd Campbell]

    Portola Pharmaceuticals’ (NASDAQ:PTLA)could have two commercial-stage drugs on the market next year, but turning them into top-sellers will require a lot of money. Is Portola Pharmaceuticals’ balance sheet flush enough with cash to get its drugs across the finish line?

  • [By Lisa Levin]

    Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 30 percent to $20.08 after announcing Phase III Betrixaban results.


    Shares of Spark Energy Inc (NASDAQ: SPKE) were down 14 percent to $20.96. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.

stock market courses: WashingtonFirst Bankshares Inc(WFBI)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of CASTLE CREEK CAPITAL PARTNERS IV, LP’s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=CASTLE+CREEK+CAPITAL+PARTNERS+IV%2C+LP

    These are the top 5 holdings of CASTLE CREEK CAPITAL PARTNERS IV, LPGuaranty Bancorp (GBNK) – 1,448,849 shares, 39.1% of the total portfolio. MBT Financial Corp (MBTF) – 1,876,423 shares, 23.6% of the total portfolio. WashingtonFirst Bankshares Inc (WFBI) – 489,377 shares, 15.19% of the total portfolio. Shares added by 4558.07%Eastern Virginia Bankshares Inc (EVBS) – 1,061,225 shares, 12.33% of the total portfolio. First NBC Bank Holding Co (FNBC) – 2,205,382 shares, 9.78% of the total portfolio. Added: Wa

stock market courses: Discover Financial Services(DFS)


Advisors’ Opinion:

  • [By Matthew Cochrane]

    While a new year has been ushered in, it is clear PayPal’s philosophy has not changed. Last week, PayPal entered into another major agreement, this time with credit card issuerDiscover Financial Services (NYSE:DFS).

  • [By JACK HOUGH]

    Like CVS, Discover has trounced the broad market over the long term but sold off recently. It’s down more than 15% this year. Costs rose early in the year in part due to one-time expenses related to anti-money-laundering efforts and other regulatory concerns. Analysts predict an offsetting decline in expenses next year. Don’t confuse Discover with a company that’s primarily in the business of running a credit-card network, like Visa (V) and MasterCard (MA). It’s basically a credit-card lender, like Capital One Financial (COF), that runs its own network to gain a competitive advantage.


    By saving on network fees, Discover can offer attractive card rewards, including a popular cash-back program. Any card lender can offer cash back, of course, but being too aggressive risks hurting margins. Discover has grown its portfolio of credit-card loans much faster than big banks have in recent years. And it has done so with industry-leading returns on capital. Rising growth could be on the way. Early this year, Discover went on a marketing spree. Last quarter, it reported its best card growth since 2007. Historically, new-card growth and loan growth have been closely correlated. In a November note to investors, Morgan Stanley analyst Cheryl Pate predicted accelerating loan growth within six months. Meanwhile, defaults remain low. Shares sell for less than 10 times projected earnings for the next four quarters, down from 12 times at the end of last year. They could rise 20% on a combination of earnings growth and a valuation rebound. The dividend yield is 2%. 

  • [By Ben Levisohn]

    We get the bull case.American Express is a blue-chip Dow component with an iconic global brand. It generates >30% returns on tangible, but it is trading well below its historical multiple and has underperformed post the election. Costco is now in the rearview mirror, and the string of negative surprises that have weighed on the stock are now poised to abate and position the company to start surprising positively. With Capital One Financial (COF), Discover Financial Services (DFS), and Synchrony Financial (SYF) all trading near their historical peaks, some have concluded thatAmerican Express is headed back to its historical high above $90. While this thought process may sound logical, we believe it only works in a world where generalists are steering the ship, and view it as highly susceptible to unraveling when negative revisions hit. American Express is not the business it once was, it doesnt have the same earnings power, and, in our view, it doesnt deserve t o trade near its historical valuation.

Leave a Reply

Your email address will not be published. Required fields are marked *